Lionheart Health, Inc., through its affiliate Leonhardt Ventures LLC, has filed a provisional patent application for a bioelectric stimulation platform designed to significantly enhance peptide uptake and biological effectiveness across oral, topical, and injectable delivery methods. The technology addresses a critical bottleneck in both biotechnology and longevity medicine: the poor bioavailability of peptide-based therapies.
According to the company, up to 70% of intravenously delivered peptides are lost, while oral and topical routes can lose 90% to 99.9% of the active compound before it reaches target tissues. The new platform applies controlled bioelectric stimulation to improve absorption and signaling efficiency. Early experimental data indicate improvements of up to 300 percent in peptide efficacy, potentially allowing lower dosing while maintaining or increasing therapeutic impact.
The patent covers a broad range of delivery routes and focuses on key healthspan-related pathways, including klotho, sirtuins, sestrins, apelin, LIM, BDNF, SDF1, PDGF, VEGF, and S100a proteins. Lionheart Health is recognized for its leadership in klotho-based longevity research and was recently named a Top 40 semifinalist in the XPRIZE Healthspan competition. The company holds multiple issued patents related to klotho technologies, with additional applications pending.
Howard J. Leonhardt, Executive Chairman, Inventor and co-CEO of Lionheart Health, Inc. and CEO of Leonhardt Ventures LLC, stated, "This filing represents a major step forward in making advanced peptide-based longevity interventions more efficient, predictable, and scalable. By combining peptides with bioelectric signaling, we believe we can unlock significantly greater biological impact at lower doses, across multiple routes of administration."
The patent describes several mechanisms of action: enhanced transmembrane transport via modulation of membrane potential; improved barrier permeability through reversible changes to tight junctions in the gut and skin; receptor sensitization via increased receptor availability; intracellular trafficking optimization to reduce peptide degradation; dose efficiency amplification; and synergistic klotho signaling to favor cellular environments that amplify longevity-related pathways.
The technology builds on decades of bioelectric medicine research by Leonhardt Ventures and expands Lionheart Health’s proprietary platform for modulating cellular environments. The company plans to incorporate the technology into upcoming healthspan initiatives and investigational protocols, while pursuing strategic partnerships and licensing opportunities. New studies will combine bioelectric stimulation-enhanced peptides with modalities such as PEMF, electromagnetic high-intensity RF, LED light, vibrational therapy, sauna, cold plunge, hyperbaric oxygen, and BodStim-enhanced exercise.
Lionheart Health, spun out of Leonhardt Ventures in 2022, is a longevity and regenerative medicine company focused on advanced bioelectric protein expression technologies, peptide science, stem cell compositions, and next-generation healthspan and medical aesthetics solutions.
